With all the indications that this drug seems to affect with a good safety profile I am surprised that the stock is not higher. Seems like it maybe too early for anyone to take notice. They had good results in kidney disease and was waiting for a peer review report on this..Anyone have any opinions on this?
News 
Market Data 
Discover 
